Danaher reported better-than-expected second-quarter results with sales of $6.3 billion, adjusted EPS of $1.94, and $1.3 billion in free cash flow. Core revenue rose 3% year over year, while the Life Sciences segment posted 5.5% core growth, its strongest quarter in several years. The company raised full-year 2026 adjusted EPS guidance to a range of $8.45 to $8.60, while keeping core revenue growth guidance at 3% to 4%. Management said bioprocessing shipment delays hurt the quarter, but underlying demand remained strong and life sciences strength is expected to offset some of that pressure.
Danaher CorporationDanaher beat Q2 estimates and raised 2026 EPS guidance.
Johnson Controls International PLC